HUP0002475A2 - Módosított immunogén pneumolizinkészítmények mint vakcinák - Google Patents
Módosított immunogén pneumolizinkészítmények mint vakcinákInfo
- Publication number
- HUP0002475A2 HUP0002475A2 HU0002475A HUP0002475A HUP0002475A2 HU P0002475 A2 HUP0002475 A2 HU P0002475A2 HU 0002475 A HU0002475 A HU 0002475A HU P0002475 A HUP0002475 A HU P0002475A HU P0002475 A2 HUP0002475 A2 HU P0002475A2
- Authority
- HU
- Hungary
- Prior art keywords
- pneumolysin
- modified
- vaccines
- compositions
- subject
- Prior art date
Links
- 101710183389 Pneumolysin Proteins 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229940031937 polysaccharide vaccine Drugs 0.000 abstract 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Abstract
A találmány tárgyát a pneumolizin módosított alakjai, azok előállításieljárásai, valamint a módosított pneumolizint kódoló nukleinsav-molekulák képezik. Szintén a találmány tárgyát képezik a találmányszerinti, módosított pneumolizint tartalmazó vakcinák, valamint azokalkalmazása emlősök - baktériumok (ideértve a Streptococcuspneumoniaet) okozta fertőzésekkel szembeni - immunizálására. Atalálmány szerinti módosított pneumolizin-polipeptidek, miközbencsökkentett toxikus aktivitással bírnak vagy egyáltalán nem toxikusak,a természetes toxin hatására termelődött antitestekkel keresztreaktívantitestek termelődését váltják ki, így alkalmasakvakcinakomponensként vagy a S. pneumoniae vagy más baktériumfertőzésekelleni konjugált poliszacharid-vakcinák immunogén hordozópolipeptidjeként. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5330697P | 1997-07-21 | 1997-07-21 | |
US7345698P | 1998-02-02 | 1998-02-02 | |
PCT/US1998/014716 WO1999003884A2 (en) | 1997-07-21 | 1998-07-21 | Modified immunogenic pneumolysin, compositions and their use as vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0002475A2 true HUP0002475A2 (hu) | 2000-10-28 |
HUP0002475A3 HUP0002475A3 (en) | 2002-01-28 |
Family
ID=26731692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0002475A HUP0002475A3 (en) | 1997-07-21 | 1998-07-21 | Modified immunogenic pneumolysin compositions as vaccines |
Country Status (9)
Country | Link |
---|---|
US (2) | US6764686B2 (hu) |
EP (1) | EP0998557A2 (hu) |
JP (1) | JP2001510031A (hu) |
KR (1) | KR100619350B1 (hu) |
AU (1) | AU740956B2 (hu) |
CA (1) | CA2297374A1 (hu) |
HU (1) | HUP0002475A3 (hu) |
NO (1) | NO20000257L (hu) |
WO (1) | WO1999003884A2 (hu) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
AR022963A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Biolog | Vacuna |
GB9906437D0 (en) * | 1999-03-19 | 1999-05-12 | Smithkline Beecham Biolog | Vaccine |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US20060034854A1 (en) | 2002-08-02 | 2006-02-16 | Berthet Francois-Xavier J | Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
EP1556477B1 (en) | 2002-11-01 | 2017-08-09 | GlaxoSmithKline Biologicals s.a. | Drying process |
CA2504938C (en) * | 2002-11-07 | 2011-10-11 | Synergy America, Inc. | Compositions and methods for treating or preventing pneumococcal infection |
NZ541969A (en) | 2003-03-13 | 2008-01-31 | Glaxosmithkline Biolog Sa | Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt |
US8574596B2 (en) | 2003-10-02 | 2013-11-05 | Glaxosmithkline Biologicals, S.A. | Pertussis antigens and use thereof in vaccination |
WO2005076696A2 (en) * | 2004-02-13 | 2005-08-25 | Sanofi Pasteur Limited | Pneumolysin derivatives |
WO2005108419A1 (en) * | 2004-05-07 | 2005-11-17 | Lea-Ann Kirkham | Mutant cholesterol-binding cytolysin proteins |
GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
CA2578361A1 (en) * | 2004-08-23 | 2006-03-02 | Genesto A/S | Binding member towards pneumolysin |
GB0421083D0 (en) * | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
CA2816182C (en) | 2005-12-22 | 2018-02-20 | Glaxosmithkline Biologicals S.A. | Pneumococcal polysaccharide conjugate vaccine |
ZA200805602B (en) | 2006-01-17 | 2009-12-30 | Arne Forsgren | A novel surface exposed haemophilus influenzae protein (protein E; pE) |
US9370557B2 (en) * | 2006-06-15 | 2016-06-21 | The University Court Of The University Of Glasgow | Adjuvant compounds |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
SI2068918T1 (sl) | 2006-09-26 | 2012-09-28 | Infectious Disease Res Inst | Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala |
EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
BRPI0717219B8 (pt) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
HUE031411T2 (hu) | 2007-03-02 | 2017-07-28 | Glaxosmithkline Biologicals Sa | Új eljárás és készítmények |
CA2683748C (en) * | 2007-04-13 | 2016-02-16 | The Board Of Regents Of The University Of Oklahoma | Mutants of cholesterol-dependent cytolysins and uses thereof |
KR101579947B1 (ko) | 2007-06-26 | 2015-12-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신 |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
MX2010011412A (es) | 2008-04-16 | 2010-11-12 | Glaxosmithkline Biolog Sa | Vacuna. |
US9125863B2 (en) * | 2008-05-22 | 2015-09-08 | Children's Medical Center Corporation | Synergistic immunogenic fusion protein-polysaccharide conjugate |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
CA2748149C (en) * | 2008-12-24 | 2018-03-06 | Netherlands Vaccine Institute | Modified steptococcus pneumonia pneumolysin (ply) polypeptides |
WO2010109324A1 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
EP2437753B1 (en) | 2009-06-05 | 2016-08-31 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them |
EP2475385A1 (en) | 2009-09-10 | 2012-07-18 | Novartis AG | Combination vaccines against respiratory tract diseases |
ES2651005T3 (es) | 2010-03-09 | 2018-01-23 | Biomedical Research Models, Inc. | Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2 |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013521770A (ja) | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
WO2011112906A2 (en) | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Novel immunogens and methods for discovery and screening thereof |
JP6002659B2 (ja) | 2010-04-13 | 2016-10-05 | セルデックス・セラピューティクス・インコーポレイテッド | ヒトcd27に結合する抗体およびその使用 |
GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
BR112013013702A2 (pt) | 2010-12-03 | 2016-09-13 | Sanofi Pasteur Ltd | composição para imunização contra streptococcus pneumoniae |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
CN103533953A (zh) | 2011-05-17 | 2014-01-22 | 葛兰素史密丝克莱恩生物有限公司 | 针对肺炎链球菌的疫苗 |
WO2013020090A2 (en) * | 2011-08-04 | 2013-02-07 | The Regents Of The University Of California | STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
MX350274B (es) | 2012-05-16 | 2017-08-31 | Immune Design Corp | Vacunas para hsv-2. |
US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
ES2847930T3 (es) | 2013-01-07 | 2021-08-04 | Mucosal Vaccine Tech Llc | Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2 |
AU2014214844B2 (en) | 2013-02-07 | 2017-12-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
BR112015025709A2 (pt) | 2013-04-18 | 2017-07-18 | Immune Design Corp | monoterapia com gla para uso em tratamento de câncer |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
CN106163551A (zh) | 2013-12-31 | 2016-11-23 | 传染性疾病研究院 | 单瓶疫苗制剂 |
US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
US10562941B2 (en) | 2014-11-21 | 2020-02-18 | The Board Of Regents Of The University Of Oklahoma | Pneumolysin mutants and methods of use thereof |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
WO2017176076A1 (en) | 2016-04-06 | 2017-10-12 | Ewha University - Industry Collaboration Foundation | A peptide with ability to penetrate cell membrane |
EA201892362A1 (ru) | 2016-04-18 | 2019-04-30 | Селлдекс Терапьютикс, Инк. | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения |
WO2017200957A1 (en) | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Pegylated liposomes and methods of use |
KR102392974B1 (ko) | 2016-05-16 | 2022-05-02 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | Tlr 작용제를 함유하는 제제 및 사용 방법 |
MX2021010105A (es) | 2016-06-01 | 2022-06-16 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento. |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
WO2018175783A1 (en) * | 2017-03-22 | 2018-09-27 | Modernatx, Inc. | Rna bacterial vaccines |
CN111315362A (zh) | 2017-06-15 | 2020-06-19 | 传染病研究所 | 纳米结构脂质载剂和稳定乳剂以及其用途 |
US20200276299A1 (en) | 2017-09-08 | 2020-09-03 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
SG11202010011RA (en) | 2018-04-17 | 2020-11-27 | Celldex Therapeutics Inc | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
JP2021535921A (ja) | 2018-09-12 | 2021-12-23 | アフィニバックス、インコーポレイテッド | 多価肺炎球菌ワクチン |
WO2020123444A1 (en) | 2018-12-11 | 2020-06-18 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
EP3894431A2 (en) | 2018-12-12 | 2021-10-20 | GlaxoSmithKline Biologicals SA | Modified carrier proteins for o-linked glycosylation |
US20220249646A1 (en) | 2019-05-25 | 2022-08-11 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
JP2024515560A (ja) | 2021-04-09 | 2024-04-10 | セルデックス セラピューティクス インコーポレイテッド | Ilt4に対する抗体、二重特異性の抗ilt4/pd-l1抗体、およびそれらの使用方法 |
WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2005704C (en) | 1988-12-16 | 2003-02-11 | James C. Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
WO1995016711A1 (es) | 1993-12-17 | 1995-06-22 | Universidad De Oviedo | Anticuerpos contra la neumolisina y sus aplicaciones |
US5565204A (en) * | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
US6019982A (en) * | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
CA2262748A1 (en) * | 1996-08-12 | 1998-02-19 | Board Of Regents, The University Of Texas System | Defining epitopes of the outer membrane protein copb of moraxella catarrhalis |
-
1998
- 1998-07-21 US US09/120,044 patent/US6764686B2/en not_active Expired - Fee Related
- 1998-07-21 CA CA002297374A patent/CA2297374A1/en not_active Abandoned
- 1998-07-21 HU HU0002475A patent/HUP0002475A3/hu unknown
- 1998-07-21 JP JP2000503106A patent/JP2001510031A/ja active Pending
- 1998-07-21 WO PCT/US1998/014716 patent/WO1999003884A2/en not_active Application Discontinuation
- 1998-07-21 KR KR1020007000844A patent/KR100619350B1/ko not_active IP Right Cessation
- 1998-07-21 EP EP98934590A patent/EP0998557A2/en not_active Withdrawn
- 1998-07-21 AU AU84078/98A patent/AU740956B2/en not_active Ceased
-
2000
- 2000-01-19 NO NO20000257A patent/NO20000257L/no not_active Application Discontinuation
-
2004
- 2004-02-23 US US10/785,673 patent/US20050070695A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU8407898A (en) | 1999-02-10 |
EP0998557A2 (en) | 2000-05-10 |
AU740956B2 (en) | 2001-11-15 |
US6764686B2 (en) | 2004-07-20 |
US20050070695A1 (en) | 2005-03-31 |
NO20000257D0 (no) | 2000-01-19 |
CA2297374A1 (en) | 1999-01-28 |
WO1999003884A2 (en) | 1999-01-28 |
WO1999003884A3 (en) | 1999-04-08 |
US20010014332A1 (en) | 2001-08-16 |
KR100619350B1 (ko) | 2006-09-05 |
HUP0002475A3 (en) | 2002-01-28 |
NO20000257L (no) | 2000-03-21 |
KR20010022271A (ko) | 2001-03-15 |
JP2001510031A (ja) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0002475A2 (hu) | Módosított immunogén pneumolizinkészítmények mint vakcinák | |
BR0009163A (pt) | Vacina | |
NL300604I2 (hu) | ||
HK1043943A1 (zh) | 肺炎鏈球菌蛋白質和疫苗 | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
BRPI0408094A (pt) | processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano | |
NO964413L (no) | Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav | |
HUP0100623A2 (hu) | Eljárások bakteriális burok-poliszacharidok extrakciójára és izolálására, azok vakcinaként vagy fehérjékhez kapcsoltan konjugátum-vakcinaként történő alkalmazására | |
ATE198051T1 (de) | Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen | |
BR9910089A (pt) | Composições e antìgenos de neisseria meningitidis | |
MX9708438A (es) | Proteina principal de la membrana externa de moraxella, de alto peso molecular. | |
TNSN07069A1 (en) | Process for concentration of antibodies and therapeutic products thereof | |
UA85993C2 (ru) | Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего | |
DK0828511T3 (da) | Haemophilus influenzae type b-vaccinesammensætning indeholdende polyribosylribitolphosphat og fremgangsmåde til fremstilling deraf | |
HUP0103502A2 (hu) | Streptococcus Cbéta-fehérje készítmények | |
ATE522541T1 (de) | Bakterielle adhäsine konformere | |
HUP0303126A2 (hu) | Vektorok molekuláknak CD11b-t expresszáló sejtekhez történő szállítására | |
WO2005032491A3 (en) | Methods and compositions for mycoplasma pneumoniae exotoxins | |
WO2002038611A3 (en) | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins | |
DE3855827T2 (de) | Bacillus thuringiensis p-2-toxingen, protein und damit in zusammenhang stehende insektizide zusammensetzungen | |
DE59704883D1 (de) | Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |